<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract SARS-CoV-2 (severe" exact="acute" post="respiratory syndrome coronavirus 2) pandemic represents the primary public"/>
 <result pre="Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract SARS-CoV-2 (severe acute" exact="respiratory" post="syndrome coronavirus 2) pandemic represents the primary public health"/>
 <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract SARS-CoV-2 (severe acute respiratory" exact="syndrome" post="coronavirus 2) pandemic represents the primary public health concern"/>
 <result pre="SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic represents the" exact="primary" post="public health concern nowadays, and great efforts are made"/>
 <result pre="of this crisis. Considerable scientific progress was recorded regarding SARS-CoV-2" exact="infection" post="in terms of genomic structure, diagnostic tools, viral transmission,"/>
 <result pre="regarding SARS-CoV-2 infection in terms of genomic structure, diagnostic tools," exact="viral" post="transmission, mechanism of viral infection, symptomatology, clinical impact, and"/>
 <result pre="terms of genomic structure, diagnostic tools, viral transmission, mechanism of" exact="viral infection," post="symptomatology, clinical impact, and complications, but these data evolve"/>
 <result pre="was also included. In addition, a comprehensible overview of SARS-CoV-2" exact="infection" post="in terms of general description and structure, mechanism of"/>
 <result pre="infection in terms of general description and structure, mechanism of" exact="viral infection," post="and clinical impact was portrayed. SARS-CoV-2 remdesivir chloroquine hydroxychloroquine"/>
 <result pre="the emergence of a novel coronavirus known as SARS-CoV-2 (severe" exact="acute" post="respiratory syndrome coronavirus 2), which caused a deadly outbreak"/>
 <result pre="emergence of a novel coronavirus known as SARS-CoV-2 (severe acute" exact="respiratory" post="syndrome coronavirus 2), which caused a deadly outbreak of"/>
 <result pre="of a novel coronavirus known as SARS-CoV-2 (severe acute respiratory" exact="syndrome" post="coronavirus 2), which caused a deadly outbreak of coronavirus"/>
 <result pre="syndrome coronavirus 2), which caused a deadly outbreak of coronavirus" exact="disease" post="(COVID-19) [1]. The first mention of this novel virus"/>
 <result pre="December 2019, and it is linked to a cluster of" exact="atypical pneumonia" post="cases (27 cases) recorded in Wuhan, Hubei province, China"/>
 <result pre="2019, and it is linked to a cluster of atypical" exact="pneumonia" post="cases (27 cases) recorded in Wuhan, Hubei province, China"/>
 <result pre="(27 cases) recorded in Wuhan, Hubei province, China [2,3]. The" exact="infection" post="was declared a pandemic on 11 March 2020 by"/>
 <result pre="pathogenic coronavirus that crossed the species barrier to cause fatal" exact="pneumonia" post="in humans, after the SARS and MERS viruses causing"/>
 <result pre="humans, after the SARS and MERS viruses causing the â€œsevere" exact="acute" post="respiratory syndromeâ€� in 2002â€&quot;2003 and the â€œMiddle East respiratory"/>
 <result pre="after the SARS and MERS viruses causing the â€œsevere acute" exact="respiratory" post="syndromeâ€� in 2002â€&quot;2003 and the â€œMiddle East respiratory syndromeâ€�"/>
 <result pre="â€œsevere acute respiratory syndromeâ€� in 2002â€&quot;2003 and the â€œMiddle East" exact="respiratory" post="syndromeâ€� in 2012, respectively [1]. It has been reported"/>
 <result pre="SARS-CoV pandemic potentially led to up to 8000 cases of" exact="infection" post="with an approximately 10% fatality rate in the early"/>
 <result pre="spread on all continents and encountering over 3,430,000 cases of" exact="infection" post="up to the date of writing this article [6]."/>
 <result pre="This review plans to offer a comprehensible overview of SARS-CoV-2" exact="infection" post="in terms of general description and structure, mechanism of"/>
 <result pre="infection in terms of general description and structure, mechanism of" exact="viral infection," post="clinical impact, and investigational anti-COVID-19 therapy. 2. Severe Acute"/>
 <result pre="of viral infection, clinical impact, and investigational anti-COVID-19 therapy. 2." exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARSâ€&quot;CoV-2)â€&quot;A Brief Portrait In"/>
 <result pre="viral infection, clinical impact, and investigational anti-COVID-19 therapy. 2. Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARSâ€&quot;CoV-2)â€&quot;A Brief Portrait In the"/>
 <result pre="infection, clinical impact, and investigational anti-COVID-19 therapy. 2. Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARSâ€&quot;CoV-2)â€&quot;A Brief Portrait In the event"/>
 <result pre="clinical impact, and investigational anti-COVID-19 therapy. 2. Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARSâ€&quot;CoV-2)â€&quot;A Brief Portrait In the event of"/>
 <result pre="Coronavirus 2 (SARSâ€&quot;CoV-2)â€&quot;A Brief Portrait In the event of a" exact="viral infection," post="and particularly when the infection has pandemic potential, identifying"/>
 <result pre="the event of a viral infection, and particularly when the" exact="infection" post="has pandemic potential, identifying the source of infection is"/>
 <result pre="when the infection has pandemic potential, identifying the source of" exact="infection" post="is decisive in controlling its spread [9]. To date,"/>
 <result pre="human coronavirus NL63 (HCoV-NL63), human coronavirus 229E (HCoV-229E), porcine transmissible" exact="gastroenteritis" post="coronavirus (TGEV), porcine epidemic diarrhea virus (PEDV), and porcine"/>
 <result pre="coronavirus 229E (HCoV-229E), porcine transmissible gastroenteritis coronavirus (TGEV), porcine epidemic" exact="diarrhea" post="virus (PEDV), and porcine respiratory coronavirus (PRCV)), betacoronavirus (e.g.,"/>
 <result pre="gastroenteritis coronavirus (TGEV), porcine epidemic diarrhea virus (PEDV), and porcine" exact="respiratory" post="coronavirus (PRCV)), betacoronavirus (e.g., SARS-CoV-2, SARS-CoV, MERS-CoV, bat coronavirus"/>
 <result pre="(PRCV)), betacoronavirus (e.g., SARS-CoV-2, SARS-CoV, MERS-CoV, bat coronavirus HKU4, mouse" exact="hepatitis" post="coronavirus (MHV), bovine coronavirus (BCoV), human coronavirus OC43, and"/>
 <result pre="and human coronavirus Hong University 1 (HCoV-HKU1)), gammacoronavirus (e.g., avian" exact="infectious" post="bronchitis coronavirus (IBV)), and deltacoronavirus (e.g., porcine deltacoronavirus (PdCV)"/>
 <result pre="human coronavirus Hong University 1 (HCoV-HKU1)), gammacoronavirus (e.g., avian infectious" exact="bronchitis" post="coronavirus (IBV)), and deltacoronavirus (e.g., porcine deltacoronavirus (PdCV) [5,12,13,14]."/>
 <result pre="and long-term severe health issues (respiratory, gastrointestinal tract infections, and" exact="central nervous system" post="illnesses in humans and animals) owing to their ability"/>
 <result pre="accessory and structural proteins (the remaining ORFs) [13]. Four main" exact="viral" post="structural proteins were described that were also detected in"/>
 <result pre="2): nucleocapsid protein (N), a helical capsid that contains the" exact="viral" post="genome; matrix/membrane protein (M) and small envelope protein (E),"/>
 <result pre="S, M, and E proteins are all embedded in the" exact="viral" post="envelope, while the N protein is located in the"/>
 <result pre="the N protein is located in the core of the" exact="viral" post="particle, forming the nucleocapsid [15]. The M proteins are"/>
 <result pre="orchestrating the assembly of the virus and in forming mature" exact="viral" post="envelopes. The E proteins are found in small quantities"/>
 <result pre="The E proteins are found in small quantities within the" exact="viral" post="particles, facilitating the release of the virions from the"/>
 <result pre="The N protein is required for RNA packaging into the" exact="viral" post="particle during viral assembly [15]; some authors consider that"/>
 <result pre="is required for RNA packaging into the viral particle during" exact="viral" post="assembly [15]; some authors consider that the N proteins"/>
 <result pre="countering the host immune response and its defense mechanisms against" exact="infections" post="[16]. Although its source is not yet confirmed, the"/>
 <result pre="the transmission chain started from bats to humans, although the" exact="intermediate" post="hosts remain undetermined [17]. The transmission of the 2002â€&quot;2003"/>
 <result pre="the accessory proteins located in the 3â€²-terminus of the genome:" exact="absence of" post="the 8a protein, a longer 8b protein consisting of"/>
 <result pre="pathogenesis is still under investigation [13]. 2.1. Mechanism of SARS-CoV-2" exact="Viral" post="Infection A major event in the viral infection is"/>
 <result pre="is still under investigation [13]. 2.1. Mechanism of SARS-CoV-2 Viral" exact="Infection" post="A major event in the viral infection is represented"/>
 <result pre="Mechanism of SARS-CoV-2 Viral Infection A major event in the" exact="viral infection" post="is represented by the binding of viral particles to"/>
 <result pre="of SARS-CoV-2 Viral Infection A major event in the viral" exact="infection" post="is represented by the binding of viral particles to"/>
 <result pre="in the viral infection is represented by the binding of" exact="viral" post="particles to cellular receptors located on host cellsâ€™ surface,"/>
 <result pre="of the major roles played by spike S glycoprotein in" exact="viral infection" post="and the impact of CoVs on human health, previous"/>
 <result pre="the major roles played by spike S glycoprotein in viral" exact="infection" post="and the impact of CoVs on human health, previous"/>
 <result pre="a large ectodomain organized in two subunitsâ€&quot;S1 and S2â€&quot;responsible for" exact="viral" post="and host membrane fusion and transfer of the genome"/>
 <result pre="host cell; (2) a single-pass transmembrane anchor; and (3) a" exact="short" post="tail located intracellularly [5,22]. The S1 subunit is involved"/>
 <result pre="(ii) CTD (C-terminal domain), which act as receptor-binding ligands ensuring" exact="viral" post="attachment [5,21,22]. Besides the key role of spike surface"/>
 <result pre="Besides the key role of spike surface glycoprotein in the" exact="viral" post="penetration into the host cells, it is also responsible"/>
 <result pre="responsible for inducing immune responses from the host and establishing" exact="viral" post="host domain and tissue tropism [5]. SARS coronaviruses, including"/>
 <result pre="[5]. SARS coronaviruses, including SARS-CoV-2, predominantly infect airway and alveolar" exact="epithelial" post="cells, vascular endothelial cells, and macrophages [23], but the"/>
 <result pre="coronaviruses, including SARS-CoV-2, predominantly infect airway and alveolar epithelial cells," exact="vascular" post="endothelial cells, and macrophages [23], but the tissue affinity"/>
 <result pre="All structures were deposited in the RCSB (Research Collaboratory for" exact="Structural" post="Bioinformatics) Protein Data Bank (PDB) under the following PDB"/>
 <result pre="were deposited in the RCSB (Research Collaboratory for Structural Bioinformatics)" exact="Protein" post="Data Bank (PDB) under the following PDB IDs: 6VW1,"/>
 <result pre="is physiologically expressed on the I and II type alveolar" exact="epithelial" post="cells of the human lung, but also by other"/>
 <result pre="to the receptor might cause cellular damage, a series of" exact="systemic" post="reactions, and even death [17]. The invasion of CoVs"/>
 <result pre="spike S glycoprotein acquires a homotrimer form noticeable from the" exact="viral" post="surface; (ii) cleavage of S glycoprotein at the boundary"/>
 <result pre="the S2â€˜ site; and (v) virusâ€&quot;cell fusion and transfer of" exact="viral" post="genome into the host cell [22]. Further, the uncoated"/>
 <result pre="of the existing literature, COVID-19 can be defined as an" exact="acute" post="respiratory syndrome that affects primarily the lungs, causing pneumonia"/>
 <result pre="the existing literature, COVID-19 can be defined as an acute" exact="respiratory" post="syndrome that affects primarily the lungs, causing pneumonia that"/>
 <result pre="existing literature, COVID-19 can be defined as an acute respiratory" exact="syndrome" post="that affects primarily the lungs, causing pneumonia that can"/>
 <result pre="an acute respiratory syndrome that affects primarily the lungs, causing" exact="pneumonia" post="that can progress to a more severe stage; that"/>
 <result pre="that can progress to a more severe stage; that is," exact="acute" post="respiratory distress syndrome (ARDS), multiorgan failure, and even death"/>
 <result pre="can progress to a more severe stage; that is, acute" exact="respiratory" post="distress syndrome (ARDS), multiorgan failure, and even death [31]."/>
 <result pre="to a more severe stage; that is, acute respiratory distress" exact="syndrome" post="(ARDS), multiorgan failure, and even death [31]. Lungs were"/>
 <result pre="the hypothesis that the transmission of SARS-CoV-2 occurs via droplets," exact="respiratory" post="fluids, and direct contact, but recent data presented novel"/>
 <result pre="transmission through environmental surfaces [32,33]. Clinically, four stages of SARS-CoV-2-induced" exact="infection" post="were described: the asymptomatic carrier state, mild-to-moderate (81% of"/>
 <result pre="critically ill (5% of cases) form [9,34]. Another classification of" exact="infection" post="stages was made according to the results obtained by"/>
 <result pre="was made according to the results obtained by non-contrast enhanced" exact="chest" post="computed tomography (CT), as follows: early stage (0â€&quot;4 days)"/>
 <result pre="stage (0â€&quot;4 days) with ground glass opacities (GGOs) in the" exact="lower" post="lung lobes; progressive stage (5â€&quot;8 days) with bilateral dissemination"/>
 <result pre="in the lower lung lobes; progressive stage (5â€&quot;8 days) with" exact="bilateral" post="dissemination of infectious process and diffuse ground glass opacities;"/>
 <result pre="lung lobes; progressive stage (5â€&quot;8 days) with bilateral dissemination of" exact="infectious" post="process and diffuse ground glass opacities; peak stage (9â€&quot;13"/>
 <result pre="stage (5â€&quot;8 days) with bilateral dissemination of infectious process and" exact="diffuse" post="ground glass opacities; peak stage (9â€&quot;13 days) with dense"/>
 <result pre="glass opacities; peak stage (9â€&quot;13 days) with dense consolidation and" exact="residual" post="parenchymal bands; and absorption stage (&amp;gt;14 days) with gradual"/>
 <result pre="they are able to spread the virus [3] through droplets," exact="respiratory" post="secretions, and direct contact [28]. The symptomatic patients with"/>
 <result pre="[3] through droplets, respiratory secretions, and direct contact [28]. The" exact="symptomatic" post="patients with mild-to-moderate to severe and rapidly progressive disease"/>
 <result pre="The symptomatic patients with mild-to-moderate to severe and rapidly progressive" exact="disease" post="present a complex symptomatic panel from mild to fatal"/>
 <result pre="mild-to-moderate to severe and rapidly progressive disease present a complex" exact="symptomatic" post="panel from mild to fatal manifestations (Figure 4), data"/>
 <result pre="updated [9]. The symptoms usually appear within 2â€&quot;14 days after" exact="viral" post="exposure [35], but this onset interval and the symptomatology"/>
 <result pre="alveolar type-1 and type-2 pneumocytes and lung stem/progenitor cells, on" exact="vascular" post="endothelial cells [36,37], in terminal ileum intestinal epithelial cells"/>
 <result pre="cells, on vascular endothelial cells [36,37], in terminal ileum intestinal" exact="epithelial" post="cells (high expression), in the colon and in the"/>
 <result pre="(high expression), in the colon and in the stomach (a" exact="lower" post="expression) [29], in the bile duct epithelial cells (a"/>
 <result pre="the stomach (a lower expression) [29], in the bile duct" exact="epithelial" post="cells (a 20Ã— higher expression than in hepatocytes) [38],"/>
 <result pre="lungs) [31], in cardiac myocytes, and in cells of the" exact="vascular" post="endothelium [36,39]. The mild-to-moderate form of the infection is"/>
 <result pre="of the vascular endothelium [36,39]. The mild-to-moderate form of the" exact="infection" post="is characterized by the following symptoms: flu-like symptomatology (fever,"/>
 <result pre="characterized by the following symptoms: flu-like symptomatology (fever, dry cough," exact="runny nose," post="and fatigue), dyspnea, expectoration, chest discomfort, respiratory distress, and"/>
 <result pre="symptomatology (fever, dry cough, runny nose, and fatigue), dyspnea, expectoration," exact="chest" post="discomfort, respiratory distress, and lymphocytopenia, which are labeled as"/>
 <result pre="dry cough, runny nose, and fatigue), dyspnea, expectoration, chest discomfort," exact="respiratory" post="distress, and lymphocytopenia, which are labeled as common symptoms,"/>
 <result pre="shivering, throat pain, anosmia, headache, joint pain, nausea, vomiting, and" exact="diarrhea" post="[17,29]. All patients exhibiting mild-to-moderate forms present abnormalities in"/>
 <result pre="diarrhea [17,29]. All patients exhibiting mild-to-moderate forms present abnormalities in" exact="chest" post="computed tomography (CT) images [17]. At the time of"/>
 <result pre="studies, this symptom became a frequently reported symptom of the" exact="infection" post="in association with dysgeusia [40,41]. In the case of"/>
 <result pre="the symptomatology is quite diverse, consisting of the following: progressive" exact="pneumonia" post="with marked inflammation, status that might deteriorate to respiratory"/>
 <result pre="progressive pneumonia with marked inflammation, status that might deteriorate to" exact="respiratory" post="failure, pulmonary edema, acute respiratory distress syndrome (ARDS), bacterial"/>
 <result pre="with marked inflammation, status that might deteriorate to respiratory failure," exact="pulmonary" post="edema, acute respiratory distress syndrome (ARDS), bacterial superinfection, septic"/>
 <result pre="inflammation, status that might deteriorate to respiratory failure, pulmonary edema," exact="acute" post="respiratory distress syndrome (ARDS), bacterial superinfection, septic shock, multiorgan"/>
 <result pre="status that might deteriorate to respiratory failure, pulmonary edema, acute" exact="respiratory" post="distress syndrome (ARDS), bacterial superinfection, septic shock, multiorgan failure,"/>
 <result pre="might deteriorate to respiratory failure, pulmonary edema, acute respiratory distress" exact="syndrome" post="(ARDS), bacterial superinfection, septic shock, multiorgan failure, and patient"/>
 <result pre="to respiratory failure, pulmonary edema, acute respiratory distress syndrome (ARDS)," exact="bacterial" post="superinfection, septic shock, multiorgan failure, and patient death [29]."/>
 <result pre="failure, pulmonary edema, acute respiratory distress syndrome (ARDS), bacterial superinfection," exact="septic shock," post="multiorgan failure, and patient death [29]. Other complications were"/>
 <result pre="were also noticed in these patients: myocardial dysfunction, arrhythmias, and" exact="acute" post="renal failure [24]. Apart from the data provided above,"/>
 <result pre="also noticed in these patients: myocardial dysfunction, arrhythmias, and acute" exact="renal failure" post="[24]. Apart from the data provided above, emerging evidence"/>
 <result pre="patients, such as anorexia (most frequent symptom in adultsâ€&quot;Chinese studies)," exact="diarrhea" post="(common both in adults and children), vomiting (more common"/>
 <result pre="[39]. It is hypothesized that the digestive disorders, liver injury," exact="acute" post="respiratory distress syndrome (ARDS), and multiorgan failure related to"/>
 <result pre="It is hypothesized that the digestive disorders, liver injury, acute" exact="respiratory" post="distress syndrome (ARDS), and multiorgan failure related to COVID-19"/>
 <result pre="hypothesized that the digestive disorders, liver injury, acute respiratory distress" exact="syndrome" post="(ARDS), and multiorgan failure related to COVID-19 have a"/>
 <result pre="triggering factorâ€&quot;â€œthe cytokine stormâ€� [29,33,42]. The virusâ€&quot;cell interactions and the" exact="viral" post="rapid replications trigger the release of multiple pro-inflammatory cytokines"/>
 <result pre="interferon gamma (IFN-Î³), granulocyte-colony stimulating factor (G-CSF), interferon-Î³-inducible protein (IP10)," exact="monocyte" post="chemoattractant protein (MCP1), macrophage inflammatory protein 1 alpha (MIP1A),"/>
 <result pre="inflammatory protein 1 alpha (MIP1A), platelet derived growth factor (PDGF)," exact="tumor" post="necrosis factor (TNF-Î±), and vascular endothelial growth factor (VEGF)"/>
 <result pre="platelet derived growth factor (PDGF), tumor necrosis factor (TNF-Î±), and" exact="vascular" post="endothelial growth factor (VEGF) [28,43]. Additionally, SARS-CoV-2 infection may"/>
 <result pre="(TNF-Î±), and vascular endothelial growth factor (VEGF) [28,43]. Additionally, SARS-CoV-2" exact="infection" post="may cause cell pyroptosis within macrophages and lymphocytes, which"/>
 <result pre="CoVs induce a local aggressive inflammation that may cause massive" exact="epithelial" post="and endothelial cell apoptosis and vascular leakage, leading to"/>
 <result pre="that may cause massive epithelial and endothelial cell apoptosis and" exact="vascular" post="leakage, leading to respiratory injury [23]. Interestingly, some studies"/>
 <result pre="epithelial and endothelial cell apoptosis and vascular leakage, leading to" exact="respiratory" post="injury [23]. Interestingly, some studies suggest that the S"/>
 <result pre="respiratory injury [23]. Interestingly, some studies suggest that the S" exact="viral" post="proteinâ€&quot;ACE2 complex is directly involved in the inflammatory responses"/>
 <result pre="can downregulate ACE2 receptors, leading to the loss of their" exact="pulmonary" post="functions, which are, unfortunately, still unknown. ACE2 dysregulations might"/>
 <result pre="dysfunction of the renin-angiotensin system as well, enhancing inflammation and" exact="vascular" post="permeability. Moreover, the ACE2 shedding has been associated with"/>
 <result pre="antibodies (anti-S-IgG) released by the host in order to fight" exact="infection" post="[23]. The antibody-dependent enhancement related to viral infection is"/>
 <result pre="order to fight infection [23]. The antibody-dependent enhancement related to" exact="viral infection" post="is a paradoxical process characterized by the presence of"/>
 <result pre="to fight infection [23]. The antibody-dependent enhancement related to viral" exact="infection" post="is a paradoxical process characterized by the presence of"/>
 <result pre="characterized by the presence of virus specific antibodies that augment" exact="viral" post="entry within host cells and replication of the pathogen,"/>
 <result pre="replication of the pathogen, leading to an exacerbation of the" exact="disease" post="[44]. In vivo studies confirmed that the presence of"/>
 <result pre="the presence of the anti-spike protein antibodies not only induced" exact="viral" post="suppression, but also caused severe acute lung injury in"/>
 <result pre="antibodies not only induced viral suppression, but also caused severe" exact="acute" post="lung injury in the early stages of SARS-CoV infection."/>
 <result pre="presented two inflammatory stages mediated by the SARS-CoVs: (i) the" exact="primary" post="stage occurs shortly after the viral infection, but prior"/>
 <result pre="the SARS-CoVs: (i) the primary stage occurs shortly after the" exact="viral infection," post="but prior to the appearance of neutralizing antibodies when"/>
 <result pre="the spike proteins and the ACE2 receptors; and (ii) the" exact="secondary" post="stage, which begins with the appearance of the antibodies"/>
 <result pre="and the generation of the adaptive immunity that can diminish" exact="viral" post="replication or trigger inflammatory responses and cause severe lung"/>
 <result pre="remains unclear, is the decreased susceptibility of children to SARS-CoV-2" exact="infection" post="as compared with the adult population. Even though an"/>
 <result pre="susceptibility of children to SARS-CoV-2 infection as compared with the" exact="adult" post="population. Even though an age-dependent susceptibility to SARS-CoV-2 infection"/>
 <result pre="as compared with the adult population. Even though an age-dependent" exact="susceptibility to" post="SARS-CoV-2 infection was established, a valid explanation for these"/>
 <result pre="the adult population. Even though an age-dependent susceptibility to SARS-CoV-2" exact="infection" post="was established, a valid explanation for these disparities is"/>
 <result pre="a high titer of antibodies in childrenâ€™s blood; (ii) a" exact="lower" post="rate of exposure to infected population; (iii) a small"/>
 <result pre="antiviral agents have been approved, and the management of coronavirus" exact="disease" post="(COVID-19) focuses mainly on supportive care and symptomatic treatment"/>
 <result pre="of coronavirus disease (COVID-19) focuses mainly on supportive care and" exact="symptomatic" post="treatment [17,35,48]. Taking into consideration the global threat posed"/>
 <result pre="a treatment for COVID-19, two approaches were nominated: (i) a" exact="short" post="term approach with immediate resultsâ€&quot;administration of approved drugs (originally"/>
 <result pre="considered at this point the most promising treatment for SARS-CoV-2" exact="infection" post="on the basis of the latest outcomes acquired within"/>
 <result pre="for SARS-CoV-2 infection on the basis of the latest outcomes" exact="acquired" post="within the phase III clinical trials sponsored by the"/>
 <result pre="the manufacturer [57] and the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) in the Adaptive COVID-19 Treatment Trial (ACTT)"/>
 <result pre="manufacturer [57] and the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) in the Adaptive COVID-19 Treatment Trial (ACTT) [58]."/>
 <result pre="(1â€²-cyano 4-aza-7,9-dideazaadenosine C-nucleosideâ€&quot;a compound that is prescribed as therapy against" exact="infectious" post="peritonitis in cats and felines, a disease determined by"/>
 <result pre="4-aza-7,9-dideazaadenosine C-nucleosideâ€&quot;a compound that is prescribed as therapy against infectious" exact="peritonitis" post="in cats and felines, a disease determined by a"/>
 <result pre="as therapy against infectious peritonitis in cats and felines, a" exact="disease" post="determined by a feline coronavirus) [59,60]. This drug was"/>
 <result pre="vitro against multiple RNA viruses, both negative sense, paramyxoviridae (parainfluenza" exact="type 3" post="virus, measles and mumps viruses, and nipah virus, among"/>
 <result pre="RNA viruses, both negative sense, paramyxoviridae (parainfluenza type 3 virus," exact="measles" post="and mumps viruses, and nipah virus, among others) and"/>
 <result pre="both negative sense, paramyxoviridae (parainfluenza type 3 virus, measles and" exact="mumps" post="viruses, and nipah virus, among others) and pneumoviridae (respiratory"/>
 <result pre="syncytial virus), and positive sense viruses, coronaviridae (SARS-CoV, MERS-CoV, mouse" exact="hepatitis" post="virus (MHV), and HCoV-OC43, among others) [60,61,62]. Structurally, RDV"/>
 <result pre="(adenosine triphosphate) competitive inhibitor, targeting an enzyme involved in the" exact="viral" post="genome replication, namely RNA-dependent RNA polymerase (RdRp) [31,48,61]. RDV"/>
 <result pre="its active triphosphate form, interfering with the action of the" exact="viral" post="RdRp of Ebola virus via insertion into the newly"/>
 <result pre="RdRp of Ebola virus via insertion into the newly nascent" exact="viral" post="RNA chain and disruption of the virus transcription [61,64,65,66]."/>
 <result pre="inhibition of RdRp complex and the premature termination of the" exact="viral" post="RNA chain [31,48]. Moreover, RDV was able to bypass"/>
 <result pre="of the antiviral mechanism of action of RDV in SARS-CoV-2" exact="infection" post="[67,68,69]. In order to investigate whether this mechanism of"/>
 <result pre="to this study, the characterized complex structure revealed that the" exact="partial" post="double-stranded RNA template was inserted into the central channel"/>
 <result pre="depicted in Figure 6 and is available in the RCSB" exact="Protein" post="Data Base under the ID 7BV2 [69]. According to"/>
 <result pre="vitro, Wang et al. proved that RDV efficiently inhibited the" exact="viral infection" post="at low-micromolar concentrations in two different cell lines (Vero"/>
 <result pre="Wang et al. proved that RDV efficiently inhibited the viral" exact="infection" post="at low-micromolar concentrations in two different cell lines (Vero"/>
 <result pre="the RDV antiviral potential by reducing clinical symptoms of the" exact="infection" post="[31]; and (iii) in clinical efficacy trials of RDV"/>
 <result pre="III clinical trials on healthy volunteers and patients with Ebola" exact="virus infection" post="asserted the pharmacokinetic properties and a safety profile of"/>
 <result pre="clinical trials on healthy volunteers and patients with Ebola virus" exact="infection" post="asserted the pharmacokinetic properties and a safety profile of"/>
 <result pre="effects occasionally occurred, such as nausea (10% of the patients)," exact="acute" post="respiratory failure (a higher percentage in the 10-day group:"/>
 <result pre="occasionally occurred, such as nausea (10% of the patients), acute" exact="respiratory" post="failure (a higher percentage in the 10-day group: 10.7%"/>
 <result pre="common adverse effects observed were nausea (10% of the patients)," exact="diarrhea" post="(5%), and headache (5% of the patients), and no"/>
 <result pre="Trial (ACTT) financed by the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAIDâ€&quot;part of the National Institutes of Health), a"/>
 <result pre="(ACTT) financed by the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAIDâ€&quot;part of the National Institutes of Health), a clinical"/>
 <result pre="patients that received placebo; in addition, the mortality rate was" exact="lower" post="in the RDV-treated group compared with placebo (8% versus"/>
 <result pre="patients [78]. These latest data regarding RDV efficacy against SARS-CoV-2" exact="infection" post="are stimulating, although the gaps concerning its safety profile"/>
 <result pre="(mainly in the case of severely ill patients with comorbiditiesâ€&quot;diabetes," exact="cardiovascular" post="pathology, and aged people) that might interfere with this"/>
 <result pre="after iv. administration (after oral administration RDV suffers an almost" exact="complete" post="first-pass hepatic clearance), distribution as a free fraction in"/>
 <result pre="adverse effects directly associated with RDV according to manufacturer data;" exact="hypersensitivity" post="reactions and renal events are also recommended to be"/>
 <result pre="increased hepatic enzymes (most common), diarrhea, rash, renal disturbance, hypotension," exact="acute" post="kidney injury, atrial fibrillation, multiple-organ dysfunction syndrome, hypernatremia, deep-vein"/>
 <result pre="hepatic enzymes (most common), diarrhea, rash, renal disturbance, hypotension, acute" exact="kidney injury," post="atrial fibrillation, multiple-organ dysfunction syndrome, hypernatremia, deep-vein thrombosis, acute"/>
 <result pre="(most common), diarrhea, rash, renal disturbance, hypotension, acute kidney injury," exact="atrial fibrillation," post="multiple-organ dysfunction syndrome, hypernatremia, deep-vein thrombosis, acute respiratory distress"/>
 <result pre="kidney injury, atrial fibrillation, multiple-organ dysfunction syndrome, hypernatremia, deep-vein thrombosis," exact="acute" post="respiratory distress syndrome, pneumothorax, hematuria, delirium, septic shock, and"/>
 <result pre="injury, atrial fibrillation, multiple-organ dysfunction syndrome, hypernatremia, deep-vein thrombosis, acute" exact="respiratory" post="distress syndrome, pneumothorax, hematuria, delirium, septic shock, and pyrexia"/>
 <result pre="hypernatremia, deep-vein thrombosis, acute respiratory distress syndrome, pneumothorax, hematuria, delirium," exact="septic shock," post="and pyrexia (most of these effects were noticed in"/>
 <result pre="the limitations of the study (small cohort size, a relatively" exact="short" post="duration of the follow-up, lack of a randomized control"/>
 <result pre="administration or are in fact consequences/complications determined by the SARS-CoV-2" exact="infection" post="[71]. One of the randomized, double-blind, placebo-controlled, multicentre clinical"/>
 <result pre="follows: most commonâ€&quot;constipation, hypoalbuminemia, hypokalemia, thrombocytopenia, anemia, and an augmented" exact="total" post="bilirubin; commonâ€&quot;increased blood glucose, rash, augmented blood lipids, high"/>
 <result pre="serum potassium, as well as rare severe adverse events as" exact="respiratory" post="failure, acute respiratory distress syndrome, and cardiopulmonary failure. Even"/>
 <result pre="as well as rare severe adverse events as respiratory failure," exact="acute" post="respiratory distress syndrome, and cardiopulmonary failure. Even though a"/>
 <result pre="well as rare severe adverse events as respiratory failure, acute" exact="respiratory" post="distress syndrome, and cardiopulmonary failure. Even though a plethora"/>
 <result pre="identifiedâ€�. Moreover, the average proportion of severe adverse events was" exact="lower" post="in the RDV-treated group compared with the placebo group"/>
 <result pre="analgesics (metamizole), antibacterials (rifabutin), anticonvulsants (eslicarbazepine, oxcarbazepine, rufinamide), anti-hypertensives for" exact="pulmonary" post="hypertension (bosentan), and steroids (betamethasone, dexamethasone) can lead to"/>
 <result pre="(metamizole), antibacterials (rifabutin), anticonvulsants (eslicarbazepine, oxcarbazepine, rufinamide), anti-hypertensives for pulmonary" exact="hypertension" post="(bosentan), and steroids (betamethasone, dexamethasone) can lead to potential"/>
 <result pre="interactions were reported; surveillance is recommended Co-administration of antidiabetics and" exact="cardiovascular" post="medication (anti-hypertensives, anticoagulants, beta blockers, and so on) is"/>
 <result pre="clinical trials, such as nausea, diarrhea, hyperlipidemia, and so on," exact="symptomatic" post="medication could be administered during RDV treatment because no"/>
 <result pre="a 70-year-old antimalaria drug, currently one of the agents for" exact="amoebiasis" post="and other protozoal diseases and antimalarials associated with irreversible"/>
 <result pre="the antimalarials and other anti-inflammatory and antirheumatic agents associated with" exact="ocular" post="toxicity and cardiomyopathy, is currently recommended in the treatment"/>
 <result pre="currently recommended in the treatment of immune diseases, such as" exact="systemic" post="lupus erythematosus and rheumatoid arthritis [83]. HCQ has been"/>
 <result pre="recommended in the treatment of immune diseases, such as systemic" exact="lupus erythematosus" post="and rheumatoid arthritis [83]. HCQ has been used for"/>
 <result pre="treatment of immune diseases, such as systemic lupus erythematosus and" exact="rheumatoid arthritis" post="[83]. HCQ has been used for the last 30"/>
 <result pre="of immune diseases, such as systemic lupus erythematosus and rheumatoid" exact="arthritis" post="[83]. HCQ has been used for the last 30"/>
 <result pre="years to treat intracellular bacterium Coxiella burnetii, which produces the" exact="Q fever," post="being the only effective agent that kills intracellular pathogens."/>
 <result pre="expression of under-glycosylated ACE2, leading to a decrease in the" exact="viral" post="spike proteinâ€&quot;cell receptor affinity [86]. In line with these"/>
 <result pre="and EL [83]â€&quot;a phase that seems to be required in" exact="viral" post="genome release, in SARS-like coronavirus infections [88]. At the"/>
 <result pre="to be required in viral genome release, in SARS-like coronavirus" exact="infections" post="[88]. At the same time, regarding the molecular mechanism"/>
 <result pre="cells and platelet function, protection of the cell surface from" exact="external" post="disorders, competitive binding to nucleic acid ligands or toll-like"/>
 <result pre="can be divided into two main categories: (1) inhibition of" exact="viral" post="enzymes/processes (viral DNA and/or RNA polymerase), glycosylation of viral"/>
 <result pre="of viral enzymes/processes (viral DNA and/or RNA polymerase), glycosylation of" exact="viral" post="proteins, assemblage of virus, new virus particle transport, and"/>
 <result pre="(ii) coadministration of HCQ with azithromycin determined the decrease of" exact="viral" post="load in COVID-19 patients [93]; (iii) CQ inhibited pneumonia"/>
 <result pre="of viral load in COVID-19 patients [93]; (iii) CQ inhibited" exact="pneumonia" post="exacerbation and shortened the infection course (improved lung imaging"/>
 <result pre="patients [93]; (iii) CQ inhibited pneumonia exacerbation and shortened the" exact="infection" post="course (improved lung imaging and increased viral clearance) [94];"/>
 <result pre="and shortened the infection course (improved lung imaging and increased" exact="viral" post="clearance) [94]; (iv) HCQ proved to be better in"/>
 <result pre="[95,96]; and (v) HCQ apparently offered no protection against SARS-CoV-2" exact="infection" post="(results of a large healthcare Israelian database analysis) [97]."/>
 <result pre="Zika viruses, as well as a preventive effect against severe" exact="respiratory" post="tract infections to patients presenting viral infection [93], but"/>
 <result pre="as well as a preventive effect against severe respiratory tract" exact="infections" post="to patients presenting viral infection [93], but further studies"/>
 <result pre="preventive effect against severe respiratory tract infections to patients presenting" exact="viral infection" post="[93], but further studies confirmed the efficacy of HCQ"/>
 <result pre="effect against severe respiratory tract infections to patients presenting viral" exact="infection" post="[93], but further studies confirmed the efficacy of HCQ"/>
 <result pre="some therapeutic benefits when compared with CQ such as a" exact="lower" post="toxicity in animals [83]. It is important to note"/>
 <result pre="use are gastrointestinal disorders, hypoglycemia, and QT interval prolongation (after" exact="short" post="term treatment), as well as cardiomyopathy and retinal toxicity"/>
 <result pre="QT interval prolongation (after short term treatment), as well as" exact="cardiomyopathy" post="and retinal toxicity (after long-term treatment) [102]. Several concerns"/>
 <result pre="days â€&quot;are higher as compared with those administered conventionally for" exact="chronic" post="therapies) in terms of cardiac toxicity and retinopathy [101,103]."/>
 <result pre="that CQ treatment induced Torsade de Pointes in a COVID-19" exact="female" post="patient [105]. Coadministration of CQ and HCQ with the"/>
 <result pre="monitoring is required, and the treatment period should be as" exact="short" post="as possible. No interactions were reported so far between"/>
 <result pre="data regarding the use of CQ and HCQ in SARS-CoV-2" exact="infection" post="are not considered robust [102], and EMA did not"/>
 <result pre="regarding the assessment of hydroxychloroquine as a treatment for COVID-19" exact="infection" post="notifies that this part of the SOLIDARITY trial was"/>
 <result pre="description in Table 2) are two antiviral drugs acting as" exact="viral" post="protease inhibitors, currently used against HIV (human immunodeficiency virus)"/>
 <result pre="acting as viral protease inhibitors, currently used against HIV (human" exact="immunodeficiency" post="virus) infection [108]. Structurally, the two compounds are 1,6-diphenyl-4-hydroxy-2,5-diaminohexane"/>
 <result pre="viral protease inhibitors, currently used against HIV (human immunodeficiency virus)" exact="infection" post="[108]. Structurally, the two compounds are 1,6-diphenyl-4-hydroxy-2,5-diaminohexane derivatives whose"/>
 <result pre="of the two compounds had a beneficial effect against CoVs" exact="infections" post="such as SARS-CoV, which triggered the investigation of their"/>
 <result pre="gene expression and replication [108] by inducing the proteolysis of" exact="viral" post="polyproteins into functional and individual units [48] consisting of"/>
 <result pre="several antivirals to act as inhibitors of the SARS-CoV specific" exact="viral" post="protease Mpro, by means of molecular docking and molecular"/>
 <result pre="was that the molecules with the best scores for potential" exact="viral" post="protease inhibition were lopinavir and ritonavir [111]. In accordance"/>
 <result pre="also revealed that Lopinavir was able to interact with the" exact="viral" post="protease predominantly through hydrophobic interactions, while in the Ritonavirâ€&quot;protease"/>
 <result pre="B and co-workers conducted a randomized, controlled, open-label trial in" exact="adult" post="hospitalized patients with COVID-19 to test the efficacy and"/>
 <result pre="combination exerted any significant antiviral effect against SARS-CoV-2, as the" exact="viral" post="RNA was still detected in 40.7% of the patients"/>
 <result pre="ascribed to this product, classified as follows: (i) very common:" exact="upper respiratory tract infection," post="diarrhea, nausea; (ii) common: lower respiratory tract infection, skin"/>
 <result pre="to this product, classified as follows: (i) very common: upper" exact="respiratory" post="tract infection, diarrhea, nausea; (ii) common: lower respiratory tract"/>
 <result pre="very common: upper respiratory tract infection, diarrhea, nausea; (ii) common:" exact="lower" post="respiratory tract infection, skin infections (including cellulitis, folliculitis, and"/>
 <result pre="common: upper respiratory tract infection, diarrhea, nausea; (ii) common: lower" exact="respiratory" post="tract infection, skin infections (including cellulitis, folliculitis, and furuncle),"/>
 <result pre="infection, diarrhea, nausea; (ii) common: lower respiratory tract infection, skin" exact="infections" post="(including cellulitis, folliculitis, and furuncle), anemia, leucopenia, neutropenia, lymphadenopathy,"/>
 <result pre="anemia, leucopenia, neutropenia, lymphadenopathy, urticaria, angioedema, blood glucose disorders including" exact="diabetes mellitus," post="hypertriglyceridemia, hypercholesterolemia, weight decrease, decreased appetite, anxiety, headache (migraine),"/>
 <result pre="appetite, anxiety, headache (migraine), insomnia, dizziness, hypertension, pancreatitis, abdominal pain," exact="hepatitis" post="(with increased AST (aspartate aminotransferase), ALT, and GGT (Gamma-glutamyl"/>
 <result pre="ALT, and GGT (Gamma-glutamyl transferase) values), skin disorders, myalgia, and" exact="erectile dysfunction," post="among others; (iii) uncommon: immune reconstitution inflammatory syndrome, hypogonadism,"/>
 <result pre="uncommon: immune reconstitution inflammatory syndrome, hypogonadism, weight increase, abnormal dreams," exact="cerebrovascular accident," post="convulsion, dysgeusia, ageusia, tremor, visual impairment, tinnitus, deep vein"/>
 <result pre="weight increase, abnormal dreams, cerebrovascular accident, convulsion, dysgeusia, ageusia, tremor," exact="visual impairment," post="tinnitus, deep vein thrombosis, gastrointestinal hemorrhage, gastrointestinal ulcer, jaundice,"/>
 <result pre="dreams, cerebrovascular accident, convulsion, dysgeusia, ageusia, tremor, visual impairment, tinnitus," exact="deep vein thrombosis," post="gastrointestinal hemorrhage, gastrointestinal ulcer, jaundice, hepatic steatosis, alopecia, rhabdomyolysis,"/>
 <result pre="impairment, tinnitus, deep vein thrombosis, gastrointestinal hemorrhage, gastrointestinal ulcer, jaundice," exact="hepatic steatosis," post="alopecia, rhabdomyolysis, osteonecrosis, and nephritis, among others; and (iv)"/>
 <result pre="rhabdomyolysis, osteonecrosis, and nephritis, among others; and (iv) rare: Stevensâ€&quot;Johnson" exact="syndrome" post="and erythema multiforme [114]. As both lopinavir and ritonavir"/>
 <result pre="and nephritis, among others; and (iv) rare: Stevensâ€&quot;Johnson syndrome and" exact="erythema multiforme" post="[114]. As both lopinavir and ritonavir are CYP3A enzyme"/>
 <result pre="wort, aliskiren, ivabradine, lercanidipine, ranolazine, sildenafil, quetiapine, antivirals such as" exact="hepatitis C" post="virus (HCV) DDAs (direct-acting antiviral agents), midazolam, triazolam, cisapride,"/>
 <result pre="liver injury, and rush [115]. In the opinion of the" exact="Infectious" post="Diseases Society of America (IDSA), the published clinical data"/>
 <result pre="injury, and rush [115]. In the opinion of the Infectious" exact="Diseases" post="Society of America (IDSA), the published clinical data concerning"/>
 <result pre="neuraminidase inhibitor, has been specifically developed for treating the influenza" exact="virus infection" post="[108]. Being structurally designed based on DANA (2,3-dehydro-2-deoxy-N-acetylneuraminic acid),"/>
 <result pre="inhibitor, has been specifically developed for treating the influenza virus" exact="infection" post="[108]. Being structurally designed based on DANA (2,3-dehydro-2-deoxy-N-acetylneuraminic acid),"/>
 <result pre="oseltamivir has an 80% bioavailability upon oral administration and a" exact="limited" post="potential for clinically relevant interactions with commonly co-administered drugs"/>
 <result pre="not terminate RNA chain elongation, but rather acts as a" exact="viral" post="mutagenesis inducing agent [125]. The drug is currently used"/>
 <result pre="[125]. The drug is currently used in the treatment of" exact="hepatitis C" post="virus (HCV) infection [124]. Using docking experiments, a research"/>
 <result pre="currently used in the treatment of hepatitis C virus (HCV)" exact="infection" post="[124]. Using docking experiments, a research team demonstrated that"/>
 <result pre="high concentrations of the drug are required to reduce the" exact="viral infection," post="as the EC50 value (109.50 Î¼M) of ribavirin was"/>
 <result pre="on influenza virus surface and blocking the fusion of the" exact="viral" post="membrane with the endosome. As SARS-CoV-2 also presents hemagglutinin"/>
 <result pre="nucleic acid purine base analog that acts primarily by inhibiting" exact="viral" post="RdRp. Other mechanisms of action reported involve RNA induced"/>
 <result pre="and Î³ subunits (at up to 100 Âµg/mL), thus being" exact="non-toxic" post="[129]. A clinical trial (ChiCTR2000029600) carried out to evaluate"/>
 <result pre="80 patients, concluded that, compared with lopinavir/ritonavir, favipiravir treatment reduced" exact="viral" post="clearance time, and 91% of patients showed improved CT"/>
 <result pre="activity [134], which might become relevant within the novel SARS-CoV-2-induced" exact="infection" post="therapy. In terms of BAâ€™s antiviral effect, recent papers"/>
 <result pre="BA causes the host cell to release virions with no" exact="infective" post="ability [134]. One of the hurdles for betulinic acid"/>
 <result pre="results against other common viruses as well such as the" exact="herpes" post="simplex virus (HSV). Phillips et al. reported that the"/>
 <result pre="improved water solubility and a stronger antiviral activity against HSV" exact="type 2" post="compared with BA [135]. Moreover, in vitro studies on"/>
 <result pre="compared with BA [135]. Moreover, in vitro studies on human" exact="lung carcinoma" post="A549 cells revealed BAâ€™s capacity to inhibit the proliferation"/>
 <result pre="with BA [135]. Moreover, in vitro studies on human lung" exact="carcinoma" post="A549 cells revealed BAâ€™s capacity to inhibit the proliferation"/>
 <result pre="of 10 ÂµM, BA showed inhibitory effects on the main" exact="viral" post="protease (3CLpro) [136], intervening in the viral replication [137]."/>
 <result pre="on the main viral protease (3CLpro) [136], intervening in the" exact="viral" post="replication [137]. Computer docking analysis revealed that BA can"/>
 <result pre="can be considered a potential adjuvant compound in treating COVID-19" exact="infectious disease." post="4.6. Anti-Inflammatory Compounds The novel COVID-19 pathology is considered"/>
 <result pre="considered the consequence of a cytokine storm, an excessive and" exact="uncontrolled" post="release of pro-inflammatory factors, leading to acute lung injury,"/>
 <result pre="an excessive and uncontrolled release of pro-inflammatory factors, leading to" exact="acute" post="lung injury, acute respiratory distress syndrome, and death [47]."/>
 <result pre="uncontrolled release of pro-inflammatory factors, leading to acute lung injury," exact="acute" post="respiratory distress syndrome, and death [47]. Therefore, anti-inflammation therapy"/>
 <result pre="release of pro-inflammatory factors, leading to acute lung injury, acute" exact="respiratory" post="distress syndrome, and death [47]. Therefore, anti-inflammation therapy might"/>
 <result pre="enzymes such as AAK1 and GAK because their inhibition reduces" exact="viral infection," post="interrupting the passage of the virus into the host"/>
 <result pre="affinity for AAK1, acting as a strong anti-inflammatory drug in" exact="chronic" post="inflammation in interferonopathies with favorable pharmacokinetic properties (low plasma"/>
 <result pre="as a main activity, they are effective anti-inflammatory agents in" exact="arthritis" post="and myelofibrosis. Their COVID-19 activity is related to the"/>
 <result pre="pathology. The most frequently reported side effects were related to" exact="upper" post="respiratory tract infections. The only concern about the use"/>
 <result pre="The most frequently reported side effects were related to upper" exact="respiratory" post="tract infections. The only concern about the use of"/>
 <result pre="from NCBI database and uses the swiss model and PHYRE2" exact="Protein" post="Fold Recognition Server to discover the spike glycoprotein [139];"/>
 <result pre="silico investigation on the mechanism played by ACE2 in inflammatory" exact="lung disease" post="to furnish some evidence for an inhibitor of SARS-CoV-2;"/>
 <result pre="investigation on the mechanism played by ACE2 in inflammatory lung" exact="disease" post="to furnish some evidence for an inhibitor of SARS-CoV-2;"/>
 <result pre="genes co-expressed with ACE2. Public data were extracted from The" exact="Cancer" post="Genome Atlas Lung Adenocarcinoma and correlation analyses between ACE2"/>
 <result pre="Public data were extracted from The Cancer Genome Atlas Lung" exact="Adenocarcinoma" post="and correlation analyses between ACE2 and 526 genes were"/>
 <result pre="show that a relevant inflammatory cytokine storm is associated with" exact="disease" post="severity [141]. Anakinra is a 17 kD recombinant, non-glycosylated"/>
 <result pre="17 kD recombinant, non-glycosylated human IL-1 receptor antagonist with a" exact="short" post="half-life of about 3â€&quot;4 h. The IL-1 receptor antagonist"/>
 <result pre="the treatment of cytokine storm syndromes, such as macrophage activation" exact="syndrome" post="and cytokine release syndrome [142]. Anakinra has a very"/>
 <result pre="storm syndromes, such as macrophage activation syndrome and cytokine release" exact="syndrome" post="[142]. Anakinra has a very safe profile and high"/>
 <result pre="high dosages have been used even in patients with severe" exact="viral" post="infections such as EBV, H1N1, and Ebola [143]. A"/>
 <result pre="dosages have been used even in patients with severe viral" exact="infections" post="such as EBV, H1N1, and Ebola [143]. A recent"/>
 <result pre="mechanical ventilation and intensive care in patients admitted for COVID-19-associated" exact="pneumonia" post="requiring oxygen therapy [144]. Up to this date, there"/>
 <result pre="is considered an effective method for the clinical treatment of" exact="infectious diseases." post="There are two main approaches in immunotherapy: passive immunization"/>
 <result pre="contains significant antibody titers might be efficient in reducing the" exact="viral" post="load and disease mortality, but there are some factors"/>
 <result pre="titers might be efficient in reducing the viral load and" exact="disease" post="mortality, but there are some factors that need to"/>
 <result pre="initiation, such as the availability of sufficient donors, clinical condition," exact="viral" post="kinetics, and host interactions of SARS-CoV-2 [12,35]. Considering the"/>
 <result pre="the imperative need to find an effective treatment against SARS-CoV-2" exact="infection" post="(which is lacking at present), administration of immune â€œconvalescentâ€�"/>
 <result pre="size studies) characterized by an improvement of clinical outcome, decreased" exact="viral" post="loads, and clinical stabilization [147]. The use of convalescent"/>
 <result pre="known, which include immunological reactions (serum sickness), transfer of other" exact="infectious" post="agents, and allergic reactions to serum constituents; and theoretical,"/>
 <result pre="constituents; and theoretical, which comprise development of antibody-dependent enhancement of" exact="infection" post="phenomenon, prevention of the infection via a pathway that"/>
 <result pre="development of antibody-dependent enhancement of infection phenomenon, prevention of the" exact="infection" post="via a pathway that reduces the immune response, and"/>
 <result pre="provide an efficient and highly specific treatment against diseases, including" exact="viral" post="infections. The monoclonal antibodies could effectively block the virus"/>
 <result pre="were an increase of hepatic enzymes values and development of" exact="opportunistic infections" post="owing to its immunomodulating activity; the other effects were"/>
 <result pre="an increase of hepatic enzymes values and development of opportunistic" exact="infections" post="owing to its immunomodulating activity; the other effects were"/>
 <result pre="interactions were reported between tocilizumab and lopinavir/ritonavir or remdesivir [80]." exact="Type I" post="interferons (IFN), especially IFN-beta, have been proposed as potential"/>
 <result pre="response, leading to tissue damage. Therefore, IFN-I treatment should be" exact="limited" post="to the early phases of the infection if this"/>
 <result pre="treatment should be limited to the early phases of the" exact="infection" post="if this hypothesis is confirmed, as shown by previous"/>
 <result pre="showed that treatment with the triple combination therapy effectively suppressed" exact="viral" post="load in all clinical admitted patients, in most cases,"/>
 <result pre="reports (retrospective analyses with a reduced number of patients), COVID-19" exact="infection" post="was adjoined with an increased susceptibility of patients to"/>
 <result pre="develop thrombotic events characterized by hemostatic disturbances (most common mild" exact="thrombocytopenia" post="and augmented level of D-dimer) and even disseminated intravascular"/>
 <result pre="common mild thrombocytopenia and augmented level of D-dimer) and even" exact="disseminated intravascular coagulation" post="(DIC). It is still unknown if the hemostatic disorders"/>
 <result pre="unknown if the hemostatic disorders are a cause of SARS-CoV-2" exact="infection" post="or a repercussion of the cytokine storm that triggers"/>
 <result pre="the cytokine storm that triggers the beginning of inflammatory response" exact="syndrome" post="(SIRS). Another hypothesis is a possible link between the"/>
 <result pre="events in COVID-19 could lie in the impairment of the" exact="vascular" post="endothelial cells (which present a high expression of ACE2"/>
 <result pre="high expression of ACE2 receptors on their surface) by the" exact="viral infection" post="[36], which triggers a hypercoagulable state by an increased"/>
 <result pre="expression of ACE2 receptors on their surface) by the viral" exact="infection" post="[36], which triggers a hypercoagulable state by an increased"/>
 <result pre="thrombin production and suppressed fibrinolysis; the final result is the" exact="coagulopathy" post="dysfunction described as one of the main causes for"/>
 <result pre="[41]. The use of LMWHs as anticoagulant therapy in COVID-19" exact="infection" post="is controversial at this time; the Chinese recommend the"/>
 <result pre="venous thrombosis, as signs of these disturbances were observed in" exact="pulmonary" post="small vessels of critically ill COVID-19 patients (occlusion and"/>
 <result pre="the use of heparin or heparin analogs in septic associated" exact="coagulopathy" post="[156]. The International Society on Thrombosis and Haemostasis (ISTH)"/>
 <result pre="analogs in septic associated coagulopathy [156]. The International Society on" exact="Thrombosis" post="and Haemostasis (ISTH) proposed a guide for anticoagulant therapy"/>
 <result pre="The reluctance in recommending LMWHs as a treatment for thromboembolic" exact="disease" post="in severely ill COVID-19s patient is based on the"/>
 <result pre="their dosage, as well as an elevated risk to produce" exact="heparin-induced thrombocytopenia" post="(a severe adverse event). It is thus recommended that"/>
 <result pre="dosage, as well as an elevated risk to produce heparin-induced" exact="thrombocytopenia" post="(a severe adverse event). It is thus recommended that"/>
 <result pre="were more missing pieces, the latest data managed to almost" exact="complete" post="the puzzle, as follows: (i) SARS-CoV-2 has a zoonotic"/>
 <result pre="(i) SARS-CoV-2 has a zoonotic origin (bats are considered the" exact="primary" post="source); (ii) the genomic structure of the virus was"/>
 <result pre="diagnostic tools and of potential novel innovative antivirals; (iii) human" exact="infection" post="requires the binding of S spike glycoprotein to the"/>
 <result pre="S spike glycoprotein to the human ACE2 receptor expressed by" exact="epithelial" post="respiratory cells, vascular endothelial cells, cardiomyocytes, gastrointestinal cells, and"/>
 <result pre="spike glycoprotein to the human ACE2 receptor expressed by epithelial" exact="respiratory" post="cells, vascular endothelial cells, cardiomyocytes, gastrointestinal cells, and hepatocytes,"/>
 <result pre="to the human ACE2 receptor expressed by epithelial respiratory cells," exact="vascular" post="endothelial cells, cardiomyocytes, gastrointestinal cells, and hepatocytes, among others;"/>
 <result pre="cells, and hepatocytes, among others; (iv) human-to-human transmission occurs via" exact="respiratory" post="droplets, direct contact, fecalâ€&quot;oral route, environmental transmission, and bodily"/>
 <result pre="route, environmental transmission, and bodily fluids (key data for the" exact="infection" post="spread repression); and (v) the clinical impact of SARS-CoV-2"/>
 <result pre="infection spread repression); and (v) the clinical impact of SARS-CoV-2" exact="infection" post="(characteristic symptomatology, onset, clinical stages, complications) is mostly described,"/>
 <result pre="being updated. The urge to find a therapy for SARS-CoV-2" exact="infection" post="determined the occurrence of multiple therapeutic alternatives, such as"/>
 <result pre="present, remdesivir is considered the most promising therapy for SARS-CoV-2" exact="infection" post="being already included in the interim guidelines for COVID-19"/>
 <result pre="debatable at this point. The use of lopinavir/ritonavir against SARS-CoV-2" exact="infection" post="determined controversial results; that is, according to some clinical"/>
 <result pre="and so on) should be recommended as therapy for SARS-CoV-2" exact="infection" post="only when the laboratory results indicate a potential â€œcytokine"/>
 <result pre="results that indicate a potential risk for thrombotic events and" exact="coagulopathy" post="disfunction; the administration of LMWHs is recommended in mild"/>
 <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
 <result pre="conflict of interest. References References 1.KhanS.SiddiqueR.ShereenM.A.AliA.LiuJ.BaiQ.BashirN.XueM.Emergence of a Novel Coronavirus," exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic OptionsJ."/>
 <result pre="of interest. References References 1.KhanS.SiddiqueR.ShereenM.A.AliA.LiuJ.BaiQ.BashirN.XueM.Emergence of a Novel Coronavirus, Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2: Biology and Therapeutic OptionsJ. Clin."/>
 <result pre="interest. References References 1.KhanS.SiddiqueR.ShereenM.A.AliA.LiuJ.BaiQ.BashirN.XueM.Emergence of a Novel Coronavirus, Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2: Biology and Therapeutic OptionsJ. Clin. Microbiol.202058e00187-2010.1128/JCM.00187-2032161092"/>
 <result pre="References References 1.KhanS.SiddiqueR.ShereenM.A.AliA.LiuJ.BaiQ.BashirN.XueM.Emergence of a Novel Coronavirus, Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2: Biology and Therapeutic OptionsJ. Clin. Microbiol.202058e00187-2010.1128/JCM.00187-2032161092 2.SohrabiC.AlsafiZ.Oâ€™NeillN.KhanM.KerwanA.Al-JabirA.IosifidisC.AghaR.World"/>
 <result pre="the 2019 novel coronavirus (COVID-19)Int. J. Surg.202076717610.1016/j.ijsu.2020.02.03432112977 3.LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.KoW.C.HsuehP.R.Asymptomatic carrier state," exact="acute" post="respiratory disease, and pneumonia due to severe acute respiratory"/>
 <result pre="2019 novel coronavirus (COVID-19)Int. J. Surg.202076717610.1016/j.ijsu.2020.02.03432112977 3.LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.KoW.C.HsuehP.R.Asymptomatic carrier state, acute" exact="respiratory" post="disease, and pneumonia due to severe acute respiratory syndrome"/>
 <result pre="(COVID-19)Int. J. Surg.202076717610.1016/j.ijsu.2020.02.03432112977 3.LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.KoW.C.HsuehP.R.Asymptomatic carrier state, acute respiratory disease, and" exact="pneumonia" post="due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2):"/>
 <result pre="carrier state, acute respiratory disease, and pneumonia due to severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and mythsJ. Microbiol."/>
 <result pre="state, acute respiratory disease, and pneumonia due to severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2): Facts and mythsJ. Microbiol. Immunol."/>
 <result pre="acute respiratory disease, and pneumonia due to severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2): Facts and mythsJ. Microbiol. Immunol. Infect.202010.1016/j.jmii.2020.02.01232173241"/>
 <result pre="2020Available online: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases(accessed on 11 May 2020) 8.collab: WHOHome Pageâ€&quot;Coronavirus" exact="Disease" post="(COVID-19) Situation Reportâ€&quot;105Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2(accessed on 5 May 2020)"/>
 <result pre="Function, and Antigenicity of the SARS-CoV-2 Spike GlycoproteinCell202018128129210.1016/j.cell.2020.02.05832155444 23.FuY.ChengY.WuY.Understanding SARS-CoV-2-Mediated" exact="Inflammatory" post="Responses: From Mechanisms to Potential Therapeutic ToolsVirol. Sin.202010.1007/s12250-020-00207-4 24.LiR.QiaoS.ZhangG.Analysis"/>
 <result pre="by SARS-CoV-2Nature202058122122410.1038/s41586-020-2179-y32225175 28.GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The Origin, Transmission and Clinical Therapies on Coronavirus" exact="Disease" post="2019 (COVID-19) Outbreakâ€&quot;An Update on the StatusMil. Med. Res.202071110.1186/s40779-020-00240-032169119"/>
 <result pre="transmission, and characteristics of human coronavirusesJ. Adv. Res.202024919810.1016/j.jare.2020.03.00532257431 31.CaoY.C.DengQ.X.DaiS.X.Remdesivir for" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 Causing COVID-19: An Evaluation"/>
 <result pre="and characteristics of human coronavirusesJ. Adv. Res.202024919810.1016/j.jare.2020.03.00532257431 31.CaoY.C.DengQ.X.DaiS.X.Remdesivir for Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 Causing COVID-19: An Evaluation of"/>
 <result pre="characteristics of human coronavirusesJ. Adv. Res.202024919810.1016/j.jare.2020.03.00532257431 31.CaoY.C.DengQ.X.DaiS.X.Remdesivir for Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 Causing COVID-19: An Evaluation of the"/>
 <result pre="of human coronavirusesJ. Adv. Res.202024919810.1016/j.jare.2020.03.00532257431 31.CaoY.C.DengQ.X.DaiS.X.Remdesivir for Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 Causing COVID-19: An Evaluation of the EvidenceTravel"/>
 <result pre="Zizyphus Jujuba on Influenza A/PR/8 VirusBiomol. Ther.20152334534910.4062/biomolther.2015.019 44.KulkarniR.Antibody-Dependent Enhancement of" exact="Viral" post="InfectionsDyn. Immune Act. Viral Dis.2019594110.1007/978-981-15-1045-8_2 45.DaviesN.G.KlepacP.LiuY.PremK.JitM.collab: CMMID COVID-19 Working"/>
 <result pre="A/PR/8 VirusBiomol. Ther.20152334534910.4062/biomolther.2015.019 44.KulkarniR.Antibody-Dependent Enhancement of Viral InfectionsDyn. Immune Act." exact="Viral" post="Dis.2019594110.1007/978-981-15-1045-8_2 45.DaviesN.G.KlepacP.LiuY.PremK.JitM.collab: CMMID COVID-19 Working GroupEggoR.M.Age-dependent Effects in the"/>
 <result pre="and Control of COVID-19 EpidemicsNat. Med.202010.1038/s41591-020-0962-9 46.XieZ.Pay attention to SARS-CoV-2" exact="infection" post="in childrenPediatric Investig.202041410.1002/ped4.12178 47.LiguoroI.PilottoC.BonanniM.FerrariM.E.PusiolA.NocerinoA.VidalE.CogoP.SARS-COV-2 infection in children and newborns:"/>
 <result pre="Med.202010.1038/s41591-020-0962-9 46.XieZ.Pay attention to SARS-CoV-2 infection in childrenPediatric Investig.202041410.1002/ped4.12178 47.LiguoroI.PilottoC.BonanniM.FerrariM.E.PusiolA.NocerinoA.VidalE.CogoP.SARS-COV-2" exact="infection" post="in children and newborns: A systematic reviewEur. J. Pediatr.202010.1007/s00431-020-03684-732424745"/>
 <result pre="Belgium 06 May 2020Version 52020 55.collab: Lombardy Section Italian Society" exact="Infectious" post="and Tropical DiseasesVademecum for the treatment of people with"/>
 <result pre="Phase 3 Trial of Investigational Antiviral Remdesivir in Patients with" exact="Severe" post="COVID-19Available online: https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19(accessed on 30 April 2020) 58.collab: A"/>
 <result pre="A NIH NIAIDNIH Clinical Trial Shows Remdesivir Accelerates Recovery from" exact="Advanced" post="COVID-19 | NIH: National Institute of Allergy and Infectious"/>
 <result pre="from Advanced COVID-19 | NIH: National Institute of Allergy and" exact="Infectious" post="DiseasesAvailable online: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19(accessed on 30 April 2020) 59.AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.SmithE.C.CaseJ.B.FengJ.Y.JordanR.et al.Coronavirus"/>
 <result pre="Infectious DiseasesAvailable online: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19(accessed on 30 April 2020) 59.AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.SmithE.C.CaseJ.B.FengJ.Y.JordanR.et al.Coronavirus" exact="Susceptibility to" post="the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral"/>
 <result pre="Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the" exact="Viral" post="Polymerase and the Proofreading ExoribonucleasemBio20189e00221-1810.1128/mBio.00221-1829511076 60.KoW.C.RolainJ.M.LeeN.Y.ChenP.L.HuangC.T.LeeP.I.HsuehP.R.Arguments in Favour of"/>
 <result pre="MoleculesSci. Rep.201774271710.1038/srep4271728256516 64.ZhangC.HuangS.ZhengF.DaiY.Controversial treatments: An updated understanding of the coronavirus" exact="disease" post="2019J. Med. Virol.202010.1002/jmv.2578832219882 65.AmirianE.S.LevyJ.K.Current Knowledge about the Antivirals Remdesivir"/>
 <result pre="analog inhibit Filo-, Pneumo-, and ParamyxovirusesSci. Rep.201774339510.1038/srep4339528262699 67.ShannonA.LeN.T.SeliskoB.EydouxC.AlvarezK.GuillemotJ.C.DecrolyE.PeersenO.FerronF.CanardB.Remdesivir and SARS-CoV-2:" exact="Structural" post="Requirements at Both nsp12 RdRp and nsp14 Exonuclease Active-SitesAntiviral"/>
 <result pre="a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe" exact="acute" post="respiratory syndrome coronavirus 2 with high potencyJ. Biol. Chem.2020956785679710.1074/jbc.RA120.013679"/>
 <result pre="direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute" exact="respiratory" post="syndrome coronavirus 2 with high potencyJ. Biol. Chem.2020956785679710.1074/jbc.RA120.013679 69.YinW.MaoC.LuanX.ShenD.D.ShenQ.SuH.WangX.ZhouF.ZhaoW.GaoM.et"/>
 <result pre="antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory" exact="syndrome" post="coronavirus 2 with high potencyJ. Biol. Chem.2020956785679710.1074/jbc.RA120.013679 69.YinW.MaoC.LuanX.ShenD.D.ShenQ.SuH.WangX.ZhouF.ZhaoW.GaoM.et al.Structural"/>
 <result pre="March 202010.20944/preprints202003.0267.v1 71.GreinJ.OhmagariN.ShinD.DiazG.AspergesE.CastagnaA.FeldtT.GreenG.GreenM.L.LescureF.X.et al.Compassionate Use of Remdesivir for Patients With" exact="Severe" post="Covid-19N. Engl. J. Med.202010.1056/NEJMoa2007016 72.WangY.ZhangD.DuG.DuR.ZhaoJ.JinY.FuS.GaoL.ChengZ.LuQ.et al.Remdesivir in adults with"/>
 <result pre="Announces Approval of VekluryÂ® (Remdesivir) in Japan for Patients with" exact="Severe" post="COVID-19Available online: https://www.gilead.com/news-and-press/press-room/press-releases/2020/5/gilead-announces-approval-of-veklury-remdesivir-in-japan-for-patients-with-severe-covid19(accessed on 19 June 2020) 76.BeigelJ.H.TomashekK.M.DoddL.E.MehtaA.K.ZingmanB.S.KalilA.C.HohmannE.ChuH.Y.LuetkemeyerA.KlineS.et al.Remdesivir"/>
 <result pre="82.YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.et al.Optimized Dosing Design of Hydroxychloroquine for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa23732150618 83.LiuJ.CaoR.XuM.WangX.ZhangH.HuH.LiY.HuZ.ZhongW.WangM.Hydroxychloroquine,"/>
 <result pre="al.Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa23732150618 83.LiuJ.CaoR.XuM.WangX.ZhangH.HuH.LiY.HuZ.ZhongW.WangM.Hydroxychloroquine, a"/>
 <result pre="Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa23732150618 83.LiuJ.CaoR.XuM.WangX.ZhangH.HuH.LiY.HuZ.ZhongW.WangM.Hydroxychloroquine, a Less"/>
 <result pre="Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa23732150618 83.LiuJ.CaoR.XuM.WangX.ZhangH.HuH.LiY.HuZ.ZhongW.WangM.Hydroxychloroquine, a Less Toxic"/>
 <result pre="Less Toxic Derivative of Chloroquine, Is Effective in Inhibiting SARS-CoV-2" exact="Infection" post="in VitroCell Discov.202061610.1038/s41421-020-0156-032194981 84.SrivastavaA.K.KumarA.TiwariG.KumarR.MisraN.In Silico Investigations on the Potential"/>
 <result pre="Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363 86.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine Is a Potent Inhibitor of SARS Coronavirus" exact="Infection" post="and SpreadVirol. J.200526910.1186/1743-422X-2-6916115318 87.SavarinoA.Di TraniL.DonatelliI.CaudaR.CassoneA.New Insights into the Antiviral"/>
 <result pre="the Antiviral Effects of ChloroquineLancet Infect. Dis.20066676910.1016/S1473-3099(06)70361-916439323 88.MingoR.M.SimmonsJ.A.ShoemakerC.J.NelsonE.A.SchornbergK.L.Dâ€™SouzaR.S.CasanovaJ.E.WhiteJ.M.Ebola Virus and" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Display Late Cell Entry Kinetics:"/>
 <result pre="Antiviral Effects of ChloroquineLancet Infect. Dis.20066676910.1016/S1473-3099(06)70361-916439323 88.MingoR.M.SimmonsJ.A.ShoemakerC.J.NelsonE.A.SchornbergK.L.Dâ€™SouzaR.S.CasanovaJ.E.WhiteJ.M.Ebola Virus and Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence"/>
 <result pre="Effects of ChloroquineLancet Infect. Dis.20066676910.1016/S1473-3099(06)70361-916439323 88.MingoR.M.SimmonsJ.A.ShoemakerC.J.NelsonE.A.SchornbergK.L.Dâ€™SouzaR.S.CasanovaJ.E.WhiteJ.M.Ebola Virus and Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence That"/>
 <result pre="of ChloroquineLancet Infect. Dis.20066676910.1016/S1473-3099(06)70361-916439323 88.MingoR.M.SimmonsJ.A.ShoemakerC.J.NelsonE.A.SchornbergK.L.Dâ€™SouzaR.S.CasanovaJ.E.WhiteJ.M.Ebola Virus and Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Display Late Cell Entry Kinetics: Evidence That Transport"/>
 <result pre="Respiratory Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence That" exact="Transport" post="to NPC1+ Endolysosomes Is a Rate-Defining StepJ. Virol.2015892931294310.1128/JVI.03398-1425552710 89.WuC.LiuY.YangY.ZhangP.ZhongW.WangY.WangQ.XuY.LiM.LiX.et"/>
 <result pre="Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated" exact="Pneumonia" post="in Clinical StudiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 95.ZhouD.DaiS.M.TongQ.COVID-19: A Recommendation to Examine"/>
 <result pre="A Recommendation to Examine the Effect of Hydroxychloroquine in Preventing" exact="Infection" post="and ProgressionJ. Antimicrob. Chemother.202010.1093/jac/dkaa114 96.MeoS.A.KlonoffD.C.AkramJ.Efficacy of Chloroquine and Hydroxychloroquine"/>
 <result pre="Pharmacol. Sci.2020244539454710.26355/eurrev_202004_2103832373993 97.GendelmanO.AmitalH.BragazziN.L.WatadA.ChodickG.Continuous Hydroxychloroquine or Colchicine Therapy Does Not Prevent" exact="Infection" post="with SARS-CoV-2: Insights from a Large Healthcare Database AnalysisAutoimmun."/>
 <result pre="Treatment of COVID-19FASEB J.2020346027603710.1096/fj.20200091932350928 103.RuamviboonsukP.LaiT.ChangA.LaiC.C.MielerW.F.LamD.collab: Asia-Pacific Vitreo-Retina SocietyChloroquine and Hydroxychloroquine" exact="Retinal" post="Toxicity Consideration in the Treatment of COVID-19Asia Pac. J."/>
 <result pre="den BroekM.MÃ¶hlmannJ.E.AbelnB.LiebregtsM.van DijkV.F.van de GardeE.Chloroquine-induced QTc Prolongation in COVID-19 PatientsNeth." exact="Heart" post="J.202010.1007/s12471-020-01429-732350818 105.SzekelyY.LichterY.ShrkiheB.A.BruckH.OsterH.S.ViskinS.Chloroquine-induced torsades de pointes in a patient with"/>
 <result pre="J.202010.1007/s12471-020-01429-732350818 105.SzekelyY.LichterY.ShrkiheB.A.BruckH.OsterH.S.ViskinS.Chloroquine-induced torsades de pointes in a patient with coronavirus" exact="disease" post="2019Heart Rhythm2020304203042310.1016/j.hrthm.2020.04.04632380291 106.collab: EMACOVID-19: Chloroquine and Hydroxychloroquine Only to"/>
 <result pre="Guidelines on the Management of Critically Ill Adults with Coronavirus" exact="Disease" post="2019Available online: https://www.esicm.org/ssc-covid19-guidelines/(accessed on 1 May 2020) 114.collab: EMAKaletra,"/>
 <result pre="Monitoring Study by Hospital Pharmacovigilance SystemClin. Pharmacol. Ther.202010.1002/cpt.1866 116.collab: IDSAInfectious" exact="Diseases" post="Society of America Guidelines on the Treatment and Management"/>
 <result pre="with COVID-19Available online: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/(accessed on 25 April 2020) 117.GoriT.LelieveldJ.MÃ¼nzelT.Perspective: Cardiovascular" exact="Disease" post="and the Covid-19 PandemicBasic Res. Cardiol.20201153210.1007/s00395-020-0792-432277299 118.BassettiM.GiacobbeD.R.AlibertiS.BarisioneE.CentanniS.De RosaF.G.Di MarcoF.GoriA.GranataG.MikulskaM.et"/>
 <result pre="Off-Label COVID-19 Drug Therapy: A Review and Proposed Monitoring ProtocolEur." exact="Heart" post="J. Acute Cardiovasc. Care202010.1177/204887262092278432372695 120.NitulescuG.M.PaunescuH.MoschosS.A.PetrakisD.NitulescuG.IonG.N.D.SpnadidosD.A.NikolouzakisT.K.DrakoulisN.TsatsakisA.Comprehensive Analysis of Drugs to"/>
 <result pre="Drug Therapy: A Review and Proposed Monitoring ProtocolEur. Heart J." exact="Acute" post="Cardiovasc. Care202010.1177/204887262092278432372695 120.NitulescuG.M.PaunescuH.MoschosS.A.PetrakisD.NitulescuG.IonG.N.D.SpnadidosD.A.NikolouzakisT.K.DrakoulisN.TsatsakisA.Comprehensive Analysis of Drugs to Treat SARS-CoV-2"/>
 <result pre="application and mechanism of action of ribavirin in therapy of" exact="hepatitis" post="CAntivir. Chem. Chemother.20122311210.3851/IMP212522592135 124.ElfikyA.A.Anti-HCV, nucleotide inhibitors, repurposing against COVID-19Life"/>
 <result pre="inhibitors, repurposing against COVID-19Life Sci.202024811747710.1016/j.lfs.2020.11747732119961 125.CrottyS.CameronC.AndinoR.Ribavirinâ€™s Antiviral Mechanism of Action:" exact="Lethal" post="Mutagenesis?J. Mol. Med.200280869510.1007/s00109-001-0308-011907645 126.ElfikyA.A.Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir"/>
 <result pre="in pathogenesisJ. Microbiol. Immunol. Infect.202010.1016/j.jmii.2020.03.022 128.DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 129.DuY.X.ChenX.P.Favipiravir: Pharmacokinetics and Concerns about"/>
 <result pre="al.Favipiravir versus Arbidol for COVID-19: A Randomized Clinical TrialmedRxiv202010.1101/2020.03.17.20037432 132.collab:" exact="Russian" post="Ministry of HealthGovernment Registry of Medicines, Medicine Registration License"/>
 <result pre="al.Specific Plant Terpenoids and Lignoids Possess Potent Antiviral Activities Against" exact="Severe" post="Acute Respiratory Syndrome CoronavirusJ. Med. Chem.2007504087409510.1021/jm070295s17663539 137.ZhangD.H.WuK.L.ZhangX.DengS.Q.PengB.In Silico Screening"/>
 <result pre="Plant Terpenoids and Lignoids Possess Potent Antiviral Activities Against Severe" exact="Acute" post="Respiratory Syndrome CoronavirusJ. Med. Chem.2007504087409510.1021/jm070295s17663539 137.ZhangD.H.WuK.L.ZhangX.DengS.Q.PengB.In Silico Screening of"/>
 <result pre="Terpenoids and Lignoids Possess Potent Antiviral Activities Against Severe Acute" exact="Respiratory" post="Syndrome CoronavirusJ. Med. Chem.2007504087409510.1021/jm070295s17663539 137.ZhangD.H.WuK.L.ZhangX.DengS.Q.PengB.In Silico Screening of Chinese"/>
 <result pre="and Lignoids Possess Potent Antiviral Activities Against Severe Acute Respiratory" exact="Syndrome" post="CoronavirusJ. Med. Chem.2007504087409510.1021/jm070295s17663539 137.ZhangD.H.WuK.L.ZhangX.DengS.Q.PengB.In Silico Screening of Chinese Herbal"/>
 <result pre="Integr. Med.20201815215810.1016/j.joim.2020.02.00532113846 138.GuptaM.K.VemulaS.DondeR.GoudaG.BeheraL.VaddeR.In-silico Approaches to Detect Inhibitors of the Human" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Envelope Protein Ion ChannelJ. Biomol."/>
 <result pre="Med.20201815215810.1016/j.joim.2020.02.00532113846 138.GuptaM.K.VemulaS.DondeR.GoudaG.BeheraL.VaddeR.In-silico Approaches to Detect Inhibitors of the Human Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Envelope Protein Ion ChannelJ. Biomol. Struct."/>
 <result pre="138.GuptaM.K.VemulaS.DondeR.GoudaG.BeheraL.VaddeR.In-silico Approaches to Detect Inhibitors of the Human Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Envelope Protein Ion ChannelJ. Biomol. Struct. Dyn.202010.1080/07391102.2020.1751300"/>
 <result pre="Approaches to Detect Inhibitors of the Human Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Envelope Protein Ion ChannelJ. Biomol. Struct. Dyn.202010.1080/07391102.2020.1751300 139.BoopathirajanP.M.K.VijayakumarK.In-Silico"/>
 <result pre="Inhibitors of the Human Severe Acute Respiratory Syndrome Coronavirus Envelope" exact="Protein" post="Ion ChannelJ. Biomol. Struct. Dyn.202010.1080/07391102.2020.1751300 139.BoopathirajanP.M.K.VijayakumarK.In-Silico Drug Discovery for"/>
 <result pre="Analysis with Structure Predicted Human â€˜ACE2-FC Region of IGG1â€™ Fusion" exact="Protein" post="As a Protein Based DrugIJCRT2020816671675 140.CavaC.BertoliG.CastiglioniI.In Silico Discovery of"/>
 <result pre="Predicted Human â€˜ACE2-FC Region of IGG1â€™ Fusion Protein As a" exact="Protein" post="Based DrugIJCRT2020816671675 140.CavaC.BertoliG.CastiglioniI.In Silico Discovery of Candidate Drugs against"/>
 <result pre="Med.202084684810.1007/s00134-020-05991-x32125452 142.La RosÃ©eP.HorneA.HinesM.von Bahr GreenwoodT.MachowiczR.BerlinerN.BirndtS.Gil-HerreraJ.GirschikofskyM.JordanM.B.et al.Recommendations for the Management of" exact="Hemophagocytic Lymphohistiocytosis" post="in AdultsBlood20191332465247710.1182/blood.201889461830992265 143.Van der VenA.J.A.M.NeteaM.G.van der MeerJ.W.M.de MastQ.Ebola Virus"/>
 <result pre="Hemophagocytic Lymphohistiocytosis in AdultsBlood20191332465247710.1182/blood.201889461830992265 143.Van der VenA.J.A.M.NeteaM.G.van der MeerJ.W.M.de MastQ.Ebola" exact="Virus Disease" post="Has Features of Hemophagocytic Lymphohistiocytosis SyndromeFront. Med.20152410.3389/fmed.2015.0000425699258 144.HuetT.BeaussierH.VoisinO.JouveshommeS.DauriatG.LazarethI.SaccoE.NaccacheJ.M.BÃ©zieY.LaplancheS.et al.Anakinra"/>
 <result pre="Lymphohistiocytosis in AdultsBlood20191332465247710.1182/blood.201889461830992265 143.Van der VenA.J.A.M.NeteaM.G.van der MeerJ.W.M.de MastQ.Ebola Virus" exact="Disease" post="Has Features of Hemophagocytic Lymphohistiocytosis SyndromeFront. Med.20152410.3389/fmed.2015.0000425699258 144.HuetT.BeaussierH.VoisinO.JouveshommeS.DauriatG.LazarethI.SaccoE.NaccacheJ.M.BÃ©zieY.LaplancheS.et al.Anakinra"/>
 <result pre="der VenA.J.A.M.NeteaM.G.van der MeerJ.W.M.de MastQ.Ebola Virus Disease Has Features of" exact="Hemophagocytic Lymphohistiocytosis" post="SyndromeFront. Med.20152410.3389/fmed.2015.0000425699258 144.HuetT.BeaussierH.VoisinO.JouveshommeS.DauriatG.LazarethI.SaccoE.NaccacheJ.M.BÃ©zieY.LaplancheS.et al.Anakinra for Severe Forms of COVID-19:"/>
 <result pre="Has Features of Hemophagocytic Lymphohistiocytosis SyndromeFront. Med.20152410.3389/fmed.2015.0000425699258 144.HuetT.BeaussierH.VoisinO.JouveshommeS.DauriatG.LazarethI.SaccoE.NaccacheJ.M.BÃ©zieY.LaplancheS.et al.Anakinra for" exact="Severe" post="Forms of COVID-19: A Cohort StudyLancet Rheumatol.202010.1016/S2665-9913(20)30164-8 145.KingA.VailA.Oâ€™LearyC.HannanC.BroughD.PatelH.GaleaJ.OgungbenroK.WrightM.PathmanabanO.et al.Anakinra"/>
 <result pre="on 4 May 2020) 150.AlattarR.IbrahimT.ShaarS.H.AbdallaS.ShukriK.DaghfalJ.N.KhatibM.Y.AboukamarM.AbukhattabM.AlsoubH.A.et al.Tocilizumab for the Treatment of" exact="Severe" post="Coronavirus Disease 2019J. Med. Virol.202010.1002/jmv.2596432369191 151.JalkanenJ.HollmÃ©nM.JalkanenS.Interferon Beta-1a for COVID-19:"/>
 <result pre="May 2020) 150.AlattarR.IbrahimT.ShaarS.H.AbdallaS.ShukriK.DaghfalJ.N.KhatibM.Y.AboukamarM.AbukhattabM.AlsoubH.A.et al.Tocilizumab for the Treatment of Severe Coronavirus" exact="Disease" post="2019J. Med. Virol.202010.1002/jmv.2596432369191 151.JalkanenJ.HollmÃ©nM.JalkanenS.Interferon Beta-1a for COVID-19: Critical Importance"/>
 <result pre="Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging ProposalJ." exact="Heart" post="Lung Transpl.20203940540710.1016/j.healun.2020.03.01232362390 153.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical Course and Risk Factors for"/>
 <result pre="Transpl.20203940540710.1016/j.healun.2020.03.01232362390 153.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical Course and Risk Factors for Mortality of" exact="Adult" post="Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort"/>
 <result pre="2 TrialLancet20203951695170410.1016/S0140-6736(20)31042-432401715 156.TangN.BaiH.ChenX.GongJ.LiD.SunZ.Anticoagulant Treatment Is Associated With Decreased Mortality in" exact="Severe" post="Coronavirus Disease 2019 Patients with CoagulopathyJ. Thromb. Haemost.2020181094109910.1111/jth.1481732220112 157.ConnorsJ.M.LevyJ.H.COVID-19"/>
 <result pre="156.TangN.BaiH.ChenX.GongJ.LiD.SunZ.Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus" exact="Disease" post="2019 Patients with CoagulopathyJ. Thromb. Haemost.2020181094109910.1111/jth.1481732220112 157.ConnorsJ.M.LevyJ.H.COVID-19 and its"/>
 <result pre="Patients with CoagulopathyJ. Thromb. Haemost.2020181094109910.1111/jth.1481732220112 157.ConnorsJ.M.LevyJ.H.COVID-19 and its implications for" exact="thrombosis" post="and anticoagulationBlood202010.1182/blood.2020006000 158.SongJ.C.WangG.ZhangW.ZhangY.LiW.Q.ZhouZ.collab: Peopleâ€™s Liberation Army Professional Committee of"/>
 <result pre="Army Professional Committee of Critical Care Medicine, Chinese Society on" exact="Thrombosis" post="and HaemostasisChinese Expert Consensus on Diagnosis and Treatment of"/>
 <result pre="and HaemostasisChinese Expert Consensus on Diagnosis and Treatment of Coagulation" exact="Dysfunction" post="in COVID-19Mil. Med. Res.202071910.1186/s40779-020-00247-732307014 Figure 1 The European Region"/>
 <result pre="in COVID-19Mil. Med. Res.202071910.1186/s40779-020-00247-732307014 Figure 1 The European Region coronavirus" exact="disease" post="(COVID-19) cases situation reported on 4 May 2020 according"/>
 <result pre="more than 5000 cases at that date) [8]. Figure 2" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) structure. This image"/>
 <result pre="than 5000 cases at that date) [8]. Figure 2 Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) structure. This image contains"/>
 <result pre="5000 cases at that date) [8]. Figure 2 Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) structure. This image contains Servier"/>
 <result pre="cases at that date) [8]. Figure 2 Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) structure. This image contains Servier Medical"/>
 <result pre="Attribution 3.0 Unported License; https://smart.servier.com. Figure 3 Mechanism of SARS-CoV-2" exact="viral" post="infection: (1) activation of S glycoprotein by transmembrane protease"/>
 <result pre="cells surface (target for CQâ€&quot;chloroquine and HCQâ€&quot;hydroxychloroquine); (3) internalization and" exact="viral" post="membrane fusion; (4) release of the uncoated RNA into"/>
 <result pre="of the host cell; (7) assembly of the newly form" exact="viral" post="RNA and the structural proteins to form the virion"/>
 <result pre="space via exocytosis; and (10) spread of the virus and" exact="viral infection." post="This image contains Servier Medical Art elements, which are"/>
 <result pre="Figure 4 Schematic overview of the steps involved in SARS-CoV-2" exact="infection" post="from the first contact with the virus until the"/>
 <result pre="bound to the template-primer RNA and triphosphate form of RDV," exact="Protein" post="Data Base (PDB) ID: 7BV2 (left); RDV covalently bound"/>
 <result pre="profile for the molecule [63]. jcm-09-02084-t001_Table 1Table 1 Interim coronavirus" exact="disease" post="(COVID-19) therapeutic guidelines in different countries dependent on clinical"/>
 <result pre="No antiviral treatment No antiviral treatment No antiviral treatment Ambulatory" exact="symptomatic" post="careâ€&quot;paracetamolâ€&quot;500 mg/3x/dayHospital treatmentâ€&quot;HCQâ€&quot;400 mg/2x/dayâ€&quot;only on day 1 and 200"/>
 <result pre="400 mgâ€&quot;12 h later and 200 mgâ€&quot;until day 5â€&quot;in the" exact="absence of" post="HCQ consider CQ base (600 mg/diagnosis; 300 mgâ€&quot;12 h"/>
 <result pre="mg/BD)â€&quot;5â€&quot;7 days LPV/r (400/100 mg/BD) (under consideration)Treatment periodâ€&quot;depending on the" exact="viral" post="excretion CQâ€&quot;5 days (under consideration day 1: 600â€&quot;300 mg;"/>
 <result pre="1 and 200 mg/2x/dayâ€&quot;4 days) + LPV/r (400/100 mg/2x/day)â€&quot;10â€&quot;14 days" exact="Severe" post="disease HCQâ€&quot;400 mg at suspicion/diagnosis; 400 mgâ€&quot;12 h later"/>
 <result pre="and 200 mg/2x/dayâ€&quot;4 days) + LPV/r (400/100 mg/2x/day)â€&quot;10â€&quot;14 days Severe" exact="disease" post="HCQâ€&quot;400 mg at suspicion/diagnosis; 400 mgâ€&quot;12 h later and"/>
 <result pre="400 mgâ€&quot;12 h later and 200 mgâ€&quot;until day 5â€&quot;in the" exact="absence of" post="HCQ consider CQ base (600 mg/diagnosis; 300 mgâ€&quot;12 h"/>
 <result pre="CQ (500 mg/BD) or HCQ (200 mg/BD)â€&quot;5â€&quot;20 days (in the" exact="absence of" post="RDV, it can be maintained LPV/r+ CQ) RDV (200"/>
 <result pre="1 followed by 100 mg/day days 2â€&quot;10)Treatment periodâ€&quot;depending on the" exact="viral" post="excretion No second option CQâ€&quot;5 days (day 1: 600â€&quot;300"/>
 <result pre="(maximum 800 mg)â€&quot;lent perfusionâ€&quot;1â€&quot;3 doses at 8 h interval Critical" exact="disease" post="RDV (compassionate use) 200 mg loading dose (IV, within"/>
 <result pre="100 mg OD for 2 to 10 days In the" exact="absence of" post="RDVâ€&quot;(HCQ, crushed in nasogastric tube, at the same dosage)"/>
 <result pre="CQ (500 mg/BD) or HCQ (200 mg/BD)â€&quot;5â€&quot;20 days (in the" exact="absence of" post="RDV, it can be maintained LPV/r+ CQ) RDV (200"/>
 <result pre="1 followed by 100 mg/day days 2â€&quot;10)Treatment periodâ€&quot;depending on the" exact="viral" post="excretion LPV/râ€&quot;as second option (case by case) RDV (for"/>
 <result pre="concentration) Dose Mechanism of Action Adverse Effects Remdesivirâ€&quot;(RDV) nucleoside analogue" exact="Severe" post="0.77 ÂµM 200 mgâ€&quot;day 1; 100 mg/dayâ€&quot;9 days inhibitor"/>
 <result pre="in the case of HCQ, the adverse effects have a" exact="lower" post="intensity, but are not absent Hydroxychloroquine (HCQ) 4-aminoquinoline Mild-to-moderate"/>
 <result pre="and increased serum triglycerides increased gamma-glutamyl transferase increased serum ALT" exact="upper respiratory tract infection" post="diarrhea nausea headache skin rush neutropenia anxiety QT prolongation"/>
 <result pre="increased serum triglycerides increased gamma-glutamyl transferase increased serum ALT upper" exact="respiratory" post="tract infection diarrhea nausea headache skin rush neutropenia anxiety"/>
 <result pre="triglycerides increased gamma-glutamyl transferase increased serum ALT upper respiratory tract" exact="infection" post="diarrhea nausea headache skin rush neutropenia anxiety QT prolongation"/>
 <result pre="increased gamma-glutamyl transferase increased serum ALT upper respiratory tract infection" exact="diarrhea" post="nausea headache skin rush neutropenia anxiety QT prolongation"/>
 <result pre="ALT upper respiratory tract infection diarrhea nausea headache skin rush" exact="neutropenia" post="anxiety QT prolongation"/>
 <result pre="upper respiratory tract infection diarrhea nausea headache skin rush neutropenia" exact="anxiety" post="QT prolongation"/>
</results>
